Quince Therapeutics, Inc. Common Stock (QNCX)

Typically moves ±11.96% on earnings

EARNINGS ANALYTICS

event_upcoming Next Earnings: 2026-11-12 HIGH CONFIDENCE

Since Feb 02, 2022, Quince Therapeutics, Inc. Common Stock (QNCX) has reported earnings 13 times. On average the shares move ±11.96% post-earnings, with a positive reaction 38.5% of the time. Its largest post-earnings gain was +18.89% (Nov 13, 2024) and its largest decline was -61.49% (Feb 12, 2026). The next earnings report is predicted for 2026-11-12 (high confidence).

Earnings reactions

How QNCX moved on each past earnings report.

Up Down

Earnings Impact

Total Earnings

Avg Abs. Movement

±11.96%

Positive %

38.5%

Negative %

61.5%

Historical Earnings Statistics

Date	Timing	Earnings move	SEC Filing
Aug 14, 2026	☀ PRE	+2.22%	open_in_new
Feb 12, 2026	☀ PRE	-61.49%	open_in_new
Nov 12, 2025	☽ POST	-2.62%	open_in_new
Aug 11, 2025	☽ POST	+15.72%	open_in_new
May 13, 2025	☀ PRE	-6.86%	open_in_new
Mar 24, 2025	☽ POST	-4.35%	open_in_new
Nov 13, 2024	☽ POST	+18.89%	open_in_new
Aug 13, 2024	☽ POST	-3.73%	open_in_new
Jul 24, 2023	☀ PRE	-25%	open_in_new
Jan 30, 2023	☽ POST	-1.2%	open_in_new
Aug 01, 2022	☀ PRE	+4.65%	open_in_new
May 12, 2022	☽ POST	+0.89%	open_in_new
Feb 02, 2022	☽ POST	-7.84%	open_in_new

event

Earnings Count

Total earnings in dataset

trending_up

Avg Abs. Movement

±11.96%

Avg % price change on earnings

description

SEC Filings

View

Browse all SEC filings

account_balance

Institutional ownership

Holdings as of Jun 30, 2026 · SEC 13-F

View all 7 →

Funds holding

$191961

Total value held

Buying

7 added · 0 reduced

Ubs Group Ag

$86039 NEW BUY

Morgan Stanley

$74288 NEW BUY

Blackrock, Inc.

$30959 NEW BUY

Barclays Plc

$491 NEW BUY

Wells Fargo & Company/Mn

$182 NEW BUY

SEC Filing Types

description 8-K

9 chevron_right

description SCHEDULE 13G

description SCHEDULE 13G/A

Recent SEC Filings

10 most recent

Form	Date Filed	View on EDGAR
8-K	20260904	open_in_new SEC.gov
8-K	20260827	open_in_new SEC.gov
DEF 14A	20260825	open_in_new SEC.gov
EFFECT	20260824	open_in_new SEC.gov
8-K	20260817	open_in_new SEC.gov
10-Q	20260814	open_in_new SEC.gov
8-K	20260814	open_in_new SEC.gov
SCHEDULE 13G/A	20260814	open_in_new SEC.gov
SCHEDULE 13G	20260814	open_in_new SEC.gov
SCHEDULE 13G	20260814	open_in_new SEC.gov

Frequently asked about QNCX earnings

When does Quince Therapeutics, Inc. Common Stock report earnings next? expand_more

Quince Therapeutics, Inc. Common Stock (QNCX)'s next earnings date is predicted (high confidence) for 2026-11-12. This is a prediction based on its historical quarterly reporting pattern, not a company-confirmed date.

How much does QNCX stock move after earnings? expand_more

Over 13 reports, QNCX has moved an average of ±11.96% the session after earnings, closing higher 38.5% of the time.

What was QNCX's biggest post-earnings move? expand_more

QNCX's largest post-earnings gain on record was +18.89% on Nov 13, 2024, and its largest decline was -61.49% on Feb 12, 2026.

Where can I find Quince Therapeutics, Inc. Common Stock's SEC filings? expand_more

All of Quince Therapeutics, Inc. Common Stock's SEC filings — 10-K, 10-Q, 8-K and more — are listed in the SEC filings section on this page, each linking to the original document on SEC.gov.